Found 225 clinical trials
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection
This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.
- 0 views
- 16 Feb, 2024
- 18 locations
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.
- 0 views
- 05 Aug, 2020
A Study to Assess Safety Tolerability and Pharmacokinetics of ABI-H3733 in Healthy Adults
This study is designed to assess safety, tolerability, pharmacokinetics (PK), formulation (liquid and solid oral forms) and food effect of ABI-H3733 in healthy participants. Part 1 includes evaluation of the safety, tolerability, and PK of ABI-H3733 during single ascending dose (SAD) and multiple-ascending dose (MAD) administration of the oral liquid …
- 0 views
- 16 Feb, 2024
- 1 location
The Renal Deterioration Between Adjusted Dose TDF and Switching to TAF in CHB With Renal Impairment
Tenofovir is a nucleotide analog drug that works against both Human immunodeficiency virus (HIV) and HBV. TDF and TAF are prodrug of Tenofovir. TAF has a higher plasma stability than TDF, which makes TDF require a higher dose to get the concentration of drugs in the liver equal to the …
- 0 views
- 16 Feb, 2024
- 1 location
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.
- 0 views
- 16 Feb, 2024
- 1 location